Armistice Capital’s RenovoRx RNXT Stock Holding History

Armistice Capital’s Portfolio RNXT Stock Details RNXT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-982,921	Closed	-$3.43M	–	268
2023 Q1	$3.43M	Buy	+982,921	New	+$3.46M	0.05%	116

Other funds holding RNXT

LBC

Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LFAS

Level Four Advisory Services Dallas, Texas $3.05B AUM 23.96% 1-Year Est. Return

ACA

Affinity Capital Advisors Berkeley, California $810M AUM 24.85% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Armistice Capital's RNXT Position: Q2 2023 in Review

Armistice Capital sold out of RenovoRx (RNXT) in Q2 2023, closing a stake of 982,921 shares — an estimated $3.43M sold.

Armistice Capital first reported a position in RNXT in Q1 2023 and held it in 1 quarter. The position peaked at $3.43M in Q1 2023. 9 funds tracked by Wall St. Rank hold RNXT as of Q2 2023.

Armistice Capital reported no remaining RenovoRx position as of Q2 2023 after selling out during the quarter.
Armistice Capital sold 982,921 RenovoRx shares in Q2 2023, an estimated $3.43M.
Armistice Capital first reported a position in RenovoRx in Q1 2023 and held it in 1 quarter.
Armistice Capital's RenovoRx position peaked at $3.43M in Q1 2023.
9 funds tracked by Wall St. Rank held RenovoRx as of Q2 2023.

Based on Armistice Capital's 13F filing for Q2 2023, filed 14 Aug 2023.